Analyzing Hyperfine (NASDAQ:HYPR) & Lifeward (NASDAQ:LFWD)

Lifeward (NASDAQ:LFWD) and Hyperfine (NASDAQ:HYPR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares Lifeward and Hyperfine”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$21.82 million	0.95	-$19.91 million	($16.82)	-0.43
Hyperfine	$11.40 million	7.35	-$35.57 million	($0.38)	-2.08

Lifeward has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lifeward and Hyperfine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lifeward	-141.28%	-235.86%	-81.72%
Hyperfine	-210.75%	-97.88%	-61.81%

Insider and Institutional Ownership

26.8% of Lifeward shares are owned by institutional investors. Comparatively, 15.0% of Hyperfine shares are owned by institutional investors. 1.5% of Lifeward shares are owned by insiders. Comparatively, 26.3% of Hyperfine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Lifeward and Hyperfine, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	1	1	2	0	2.25
Hyperfine	1	1	3	0	2.40

Lifeward currently has a consensus target price of $10.00, indicating a potential upside of 36.80%. Hyperfine has a consensus target price of $2.03, indicating a potential upside of 157.38%. Given Hyperfine’s stronger consensus rating and higher possible upside, analysts clearly believe Hyperfine is more favorable than Lifeward.

Volatility & Risk

Lifeward has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Hyperfine has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Summary

Hyperfine beats Lifeward on 9 of the 14 factors compared between the two stocks.

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

About Hyperfine

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.